Clinical study on using recombinant human granulocyte colony stimulating factor(rhG-CSF) in high-dose combined chemotherapy of osteosarcoma

Objective The clinical usefulness of rhG CSF was evaluated in patients with leukopenia and neutropenia induced by high dose combined chemotherapy for osteosarcoma and rhG CSF′s side effects.Methods A series of 58 osteosarcoma patients were divided into study group and control group (according their economic situation) and were treated with same chemotherapy regimen.rhG CSF at a dose of 150 μg/body daily was given subcutaneously 72 h after the termination of chemotherapy for five to seven days in study group.While normal medicine was given in control group.Results rhG CSF significantly increased the total white cell count (WBC) and absolute neutrophil count (ANC) at nadir,and shortened the duration of leukopenia with WBC4 0×10 9/L and ANC2 5×10 9/L,reduced the number of recovery days to normal and increased the completeness rate of chemotherapy.The side effect of rhG CSF was mild and tolerable.Conclusion rhG CSF is effective against the decrease of WBC and ANC,is able to improve chemotherapy′s success rate;using rhG CSF is an effective remedy for preventing and treating the bone marrow arrest induced by chemotherapy.